-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KXBwARf5pHCUuxnYL/Jnj1F5pPiA1RbubXpXbJNHjYAg0vsRV2dhzf13Hcg5pSvS KC6HJArtlLarNGUbWzz4Bw== 0001230295-07-000068.txt : 20070109 0001230295-07-000068.hdr.sgml : 20070109 20070109155150 ACCESSION NUMBER: 0001230295-07-000068 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061229 FILED AS OF DATE: 20070109 DATE AS OF CHANGE: 20070109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KLEIN JOSEPH III CENTRAL INDEX KEY: 0001206369 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 07520616 BUSINESS ADDRESS: BUSINESS PHONE: 2037731450 MAIL ADDRESS: STREET 1: C/O GENAISSANCE PHARMACEUTICALS INC STREET 2: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 4/A 1 kle142.xml X0202 4/A 2006-12-29 2007-01-04 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001206369 KLEIN JOSEPH III C/O SAVIENT PHARMACEUTICALS, INC ONE TOWER CENTER BLVD., 14TH FLOOR EAST BRUNSWICK NJ 08816 1 0 0 0 Common Stock, $.01 par value per share 2006-12-29 4 A 0 334 11.2100 A 45216.0000 D Option to Purchase Common Stock, $.01 par value 11.2100 2006-12-29 4 A 0 5000 11.2100 A 2007-12-29 2016-12-29 Common Stock, $.01 par value per share 5000.0000 5000.0000 D These shares were granted pursuant to the Company's 2004 Incentive Plan, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $3,750.00, until he is no longer an Outside Director. On December 29, 2006, the fair market value of the Common Stock, based on the closing price, was $11.21. Note, these shares were inadvertently left off the timely filed Form 4 from 1/4/07. These options will become fully vested and immediately exercisable on 12/29/2007. By: Michelle Zelinski as Attorney-In-Fact for 2007-01-09 -----END PRIVACY-ENHANCED MESSAGE-----